Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
R. Laduane Clifton is CFO & Treasurer at Zevra Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Feb 14, 2025, each linked to the official Form 4.
CFO & Treasurer
Disclosures on record
1
Companies involved
1
As of the latest filing on , R. Laduane Clifton reported holding 51,361 shares of Zevra Therapeutics (ZVRA), worth about $483K at the last close of $9 (Nov 17, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Zevra Therapeutics ZVRA | 51,361 | 51K direct | $9 | $483K | Feb 13, 2025 |
Is this R. Laduane Clifton’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Feb 13, 2025Sold~$86Kdisclosed Feb 14
DetailsOfficial recordOn the latest SEC Form 4, dated Feb 13, 2025, R. Laduane Clifton reported holding 51,361 shares of Zevra Therapeutics (ZVRA). At the last close of $9 on Nov 17, 2026, that is about $483K. This is the stake disclosed in filings, not a net worth.
R. Laduane Clifton bought shares on the open market in 10 different years since 2010, and has not bought since 2024 across 2 companies. Sales in 1 of the 17 years since 2010.
In SEC filings since 2010: the latest open-market purchase is from 2024; the latest open-market sale is from 2025.
2 companies: Zevra Therapeutics (ZVRA, 2017–2025), Lgl Group (LGL, 2010–2011).
R. Laduane Clifton bought shares on the open market in 10 different years since 2010, and has not bought since 2024 across 2 companies. Sales in 1 of the 17 years since 2010.
R. Laduane Clifton reported 39 open-market purchases and 1 sale since 2010; purchases in 10 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $86K1×1 trade |
| 2024 | $14K1×1 trade | — |
| 2023 | $29K7×7 trades | — |
| 2022 |
$12K3×3 trades |
| — |
| 2021 | $19K6×6 trades | — |
| 2020 | $6.8K6×6 trades | — |
| 2019 | $11K7×7 trades | — |
| 2018 | $4.9K2×2 trades | — |
| 2017 | $6.3K4×4 trades | — |
| 2011 | $9502×2 trades | — |
| 2010 | $1.2K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
R. Laduane Clifton reported 36 open-market purchases and 1 sale here, 2017 to 2025.
R. Laduane Clifton reported 3 open-market purchases and 0 sales here, 2010 to 2011.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.